Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet α-granule content and primary activation

International Journal of Biological Markers

Volumn 19, Issue 3, 2004, Pages 221-228

  Gonzalez, Francisco Jesus ^a   Rueda, A ^a   Sevilla, I ^a   Alonso, L ^a   Villarreal, V ^a   Torres, E ^a   Alba, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Angiogenesis; Cancer; Plasma; Serum; Thrombospondin; TSP 1; Vascular endothelial growth factor; VEGF

Indexed keywords

THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; TUMOR VASCULARIZATION;

EID: 6444230712     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1959     Document Type: Article

References (34)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nature Rev 2002; 2: 795-803.
2. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5: 487-91.
3. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
4. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-89.
5. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
6. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-8.
7. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990; 111: 765-72.
8. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6: 1-12.
9. Tuszyinski GP, Srivastava S, Switalska HI, Holt JC, Cierniewski CS, Niewiarowski S. The interaction of human platelet thrombospondin with fibrinogen: thrombospondin purification and specificity of interaction. J Biol Chem 1985; 260: 12240-5.
10. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001; 7: 401-7.
11. Tuszynski GP, Smith M, Rothman VL, et al. Thrombospondin levels in patients with malignancy. Thromb Haemost 1992; 67: 607-11.
12. Nathan FE, Hernandez E, Dunton CJ, et al. Plasma throm-bospondin levels in patients with gynecologic malignancies. Cancer 1994; 73: 2853-8.
13. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-64.
14. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen? Int J Oncol 2000; 17: 149-52.
15. Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-74.
16. Adams J, Cader PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60: 2898-905.
17. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to studying an angiogenic marker in vivo?. Ann Oncol 1999; 10: 965-71.
18. Dittadi R, Meo S, Fabris F, et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001; 16: 87-96.
19. Hormbrey E, Gillespie P, Turner K, et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: Is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651-63.
20. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147-52.
21. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16: 5-26.
22. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T, Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 1998; 82: 632-8.
23. Brostjan C, Bayer A, Zommer A, et al. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 2003; 98: 2291-301.
24. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
25. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-4.
26. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2001; 2: 608-13.
27. Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892-7.
28. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343-50.
29. Dawes J, Pratt DA, Dewar MS, Preston FE. Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb Haemost 1988; 59: 273-6.
30. Dawes J, Clemetson KJ, Gogstad GO, et al. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb Res 1983; 29: 569-81.
31. Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51: 296-301.
32. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3: 425-30.
33. Macko RF, Gelber AC, Young BA, et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002; 29: 2565-70.
34. Bastida E, Ordinas A. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis 1988; 18: 29-36.